Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2020.102642 http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102642 33321356!7955770!33321356     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler+Relat+Disord 2021 ; 47 (ä): 102642 Nephropedia Template TP {{tp|p=33321356|t=2021. Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic |pdf=|usr=}}{{33321356}} gab.com Text Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=33321356 #FOAvip BACKGROUND: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients. OBJECTIVE: To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic. METHODS: Patients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed. RESULTS: We analysed 269 rapid natalizumab infusions and 100 rapid ocrelizumab infusions. Infusion related reactions during the natalizumab or ocrelizumab infusions occurred in two patients (1.52%) and eight patients (8%), respectively. All infusion related reactions were mild to moderate and did not require infusion discontinuation. No infusion reactions occurred during the post-infusion observation. Patient experience was positive. CONCLUSION: Frequency or severity of infusion related reactions in rapid infusions were no different compared to published data. In the setting of COVID-19, pandemic rapid infusion protocols could potentially save hospital resources and limit patient exposure to a high-risk clinical setting while still maintaining ongoing treatment of multiple sclerosis. Twit Text FOAVip Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=33321356 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33321356 #FOAvip English Wikipedia <ref>{{Cite pmid|33321356}}</ref> Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic #MMPMID33321356 Rath L; Bui MV; Ellis J; Carey J; Baker J; Taylor L; Fernando H; Taylor N; Savage P; Richards J; Zhong M; Kalincik T; Skibina O; Wesselingh R; Nguyen AL; Monif M; Butzkueven H; van der Walt A Mult Scler Relat Disord 2021[Jan]; 47 (ä): 102642 PMID33321356show ga BACKGROUND: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients. OBJECTIVE: To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic. METHODS: Patients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed. RESULTS: We analysed 269 rapid natalizumab infusions and 100 rapid ocrelizumab infusions. Infusion related reactions during the natalizumab or ocrelizumab infusions occurred in two patients (1.52%) and eight patients (8%), respectively. All infusion related reactions were mild to moderate and did not require infusion discontinuation. No infusion reactions occurred during the post-infusion observation. Patient experience was positive. CONCLUSION: Frequency or severity of infusion related reactions in rapid infusions were no different compared to published data. In the setting of COVID-19, pandemic rapid infusion protocols could potentially save hospital resources and limit patient exposure to a high-risk clinical setting while still maintaining ongoing treatment of multiple sclerosis. |*COVID-19[MESH] |Adult[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |Female[MESH] |Humans[MESH] |Immunologic Factors/*administration & dosage[MESH] |Infusions, Intravenous/adverse effects/*methods[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis, Relapsing-Remitting/*drug therapy[MESH] |Natalizumab/*administration & dosage[MESH]Fast and safe: Optimising multiple sclerosis infusions during COVID-19(epmc).pdf DeepDyve Pubget Overpricing